Assenagon Asset Management S.A. Has $43.72 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assenagon Asset Management S.A. lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 350,052 shares of the biotechnology company's stock after selling 9,644 shares during the period. Assenagon Asset Management S.A. owned approximately 0.37% of Sarepta Therapeutics worth $43,718,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Wealth Enhancement Advisory Services LLC increased its stake in Sarepta Therapeutics by 100.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company's stock valued at $647,000 after acquiring an additional 2,504 shares during the period. Hudson Capital Management LLC bought a new position in Sarepta Therapeutics during the first quarter valued at about $220,000. Commonwealth Equity Services LLC increased its stake in Sarepta Therapeutics by 8.7% during the first quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company's stock valued at $679,000 after acquiring an additional 418 shares during the period. Van ECK Associates Corp increased its stake in Sarepta Therapeutics by 5.3% during the first quarter. Van ECK Associates Corp now owns 86,329 shares of the biotechnology company's stock valued at $11,176,000 after acquiring an additional 4,374 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Sarepta Therapeutics by 111.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company's stock valued at $12,131,000 after acquiring an additional 47,895 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the company's stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Citigroup lowered their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research note on Monday. They issued a "buy" rating and a $165.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Finally, Barclays lowered their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $182.95.

Sarepta Therapeutics Stock Down 0.7 %

Shares of SRPT stock traded down $0.88 during trading on Friday, reaching $131.14. The company's stock had a trading volume of 849,643 shares, compared to its average volume of 1,243,304. The business has a fifty day moving average price of $128.78 and a 200-day moving average price of $132.40. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market cap of $12.40 billion, a price-to-earnings ratio of 1,200.18 and a beta of 0.82. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. Analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.